Cellular imaging in drug discovery

Nature Reviews Drug Discovery

Volumn 5, Issue 4, 2006, Pages 343-356

  Lang, Paul ^a   Yeow, Karen ^a   Nichols, Anthony ^a   Scheer, Alexander ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RECEPTOR BLOCKING AGENT;

BIOLUMINESCENCE; CELL COUNT; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL SHAPE; CYTOLOGY; DEVICE; DIGITAL IMAGING; DRUG RESEARCH; DRUG SCREENING; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUOROMETRY; HIGH THROUGHPUT SCREENING; HUMAN; IMAGING SYSTEM; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RNA INTERFERENCE;

EID: 33645464806     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: None     Document Type: Article

References (133)

1. Hood, L. & Perlmutter, R. M. The impact of systems approaches on biological problems in drug discovery. Nature Biotechnol. 22, 1215-1217 (2004).
2. Sams-Dodd, F. Target-based drug discovery: Is something wrong? Drug Discov. Today 10, 139-147 (2005).
3. Besson, D., Yeow, K., Lang, P. & Scheer, A. HTS and cellular biology at Serono. Curr. Drug Discov. 29-32 (2003).
4. Comley, J. High content screening: Emerging importance of novel reagents/ probes and pathway analysis. Drug Discov. World 6, 31-54 (2005).
5. Ramm, P. Image-based screening: A technology in transition. Curr. Opin. Biotechnol. 16, 41-48 (2005).
6. Bivona, T. G. & Philips, M. R. Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains. Methods 37, 138-145 (2005).
7. Voss, T. C., Demarco, I. A. & Day, R. N. Quantitative imaging of protein interactions in the cell nucleus. Biotechniques 38, 413-424 (2005).
8. Sekar, R. B. & Periasamy, A. Fluorescence resonance energy transfer (FRET) microscopy imaging of live cell protein localizations. J. Cell Biol. 160, 629-633 (2003).
9. Errington, R. J. et al. Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells. Adv. Drug Deliv. Rev. 57, 153-167 (2005).
10. von Arnim, C. A. et al. The low density lipoprotein receptor-related protein (LRP) is a novel β-secretase (BACE1) substrate. J. Biol. Chem. 280, 17777-17785 (2005).
11. Herzenberg, L. A. et al. The history and future of the fluorescence activated cell sorter and flow cytometry: A view from Stanford. Clin. Chem. 48, 1819-1827 (2002).
12. Geuijen, C. A. et al. Affinity ranking of antibodies using flow cytometry: Application in antibody phage display-based target discovery. J. Immunol. Methods 302, 68-77 (2005).
13. Florian, S. et al. Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk. Lymphoma 47, 207-222 (2006).
14. Heinemann, A. et al. Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling. J. Immunol. 165, 7224-7233 (2000).
15. Tanaka, M. et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 3, e128 (2005).
16. Miller, S. C. & Mitchison, T. J. Synthesis and phenotypic screening of a guanine-mimetic library. Chembiochem. 5, 1010-1012 (2004).
17. Yarrow, J. C., Feng, Y., Perlman, Z. E., Kirchhausen, T. & Mitchison, T. J. Phenotypic screening of small molecule libraries by high throughput cell imaging. Comb. Chem. High Throughput. Screen. 6, 279-286 (2003).
18. Yarrow, J. C., Totsukawa, G., Charras, G. T. & Mitchison, T. J. Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem. Biol. 12, 385-395 (2005).
19. Ramm, P. et al. Automated screening of neurite outgrowth. J. Biomol. Screen. 8, 7-18 (2003).
20. Richards, G. R., Millard, R. M., Leveridge, M., Kerby, J. & Simpson, P. B. Quantitative assays of chemotaxis and chemokinesis for human neural cells. Assay. Drug Dev. Technol. 2, 465-472 (2004).
21. Bahnson, A. et al. Automated measurement of cell motility and proliferation. BMC Cell Biol. 6, 19 (2005).
22. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
23. Eggert, U. S. et al. Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets. PLoS Biol. 2, e379 (2004).
24. Mattheakis, L. C. et al. Optical coding of mammalian cells using semiconductor quantum dots. Anal. Biochem. 327, 200-208 (2004).
25. Edwards, B. S., Oprea, T., Prossnitz, E. R. & Sklar, L. A. Flow cytometry for high-throughput, high-content screening. Curr. Opin. Chem. Biol. 8, 392-398 (2004).
26. Irish, J. M. et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118, 217-228 (2004).
27. Morgan, E. et al. Cytometric bead array: A multiplexed assay platform with applications in various areas of biology. Clin. Immunol. 110, 252-266 (2004).
28. Wong, C. K., Cheung, P. F., Ip, W. K. & Lam, C. W. Interleukin-25-induced chemokines and interleukin-6 release from eosinophils is mediated by p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and nuclear factor-κB. Am. J. Respir. Cell Mol. Biol. 33, 186-194 (2005).
29. Rausch, O. Use of high-content analysis for compound screening and target selection. IDrugs 8, 573-577 (2005).
30. Ramm, P. Imaging systems in assay screening. Drug Discov. Today 4, 401-410 (1999).
31. Wu, C. C., Reilly, J. F., Young, W. G., Morrison, J. H. & Bloom, F. E. High-throughput morphometric analysis of individual neurons. Cereb. Cortex 14, 543-554 (2004).
32. Burnett, P. et al. Fluorescence imaging of electrically stimulated cells. J. Biomol. Screen. 8, 660-667 (2003).
33. Ramm, P. Advanced image analysis systems in cell, molecular and neurobiology applications. J. Neurosci. Methods 54, 131-149 (1994).
34. Takahashi, Y., Sawada, R., Ishibashi, K., Mikuni, S. & Kinjo, M. Analysis of cellular functions by multipoint fluorescence correlation spectroscopy. Curr. Pharm. Biotechnol. 6, 159-165 (2005).
35. Wouters, F. S., Verveer, P. J. & Bastiaens, P. I. Imaging biochemistry inside cells. Trends Cell Biol. 11, 203-211 (2001).
36. Watson, P., Jones, A. T. & Stephens, D. J. Intracellular trafficking pathways and drug delivery: Fluorescence imaging of living and fixed cells. Adv. Drug Deliv. Rev. 57, 43-61 (2005).
37. Gasparri, F., Mariani, M., Sola, F. & Galvani, A. Quantification of the proliferation index of human dermal fibroblast cultures with the ArrayScan high-content screening reader. J. Biomol. Screen. 9, 232-243 (2004).
38. Schroeder, K. S. & Neagle, B. D. FLIPR: A new instrument for accurate, high throughput optical screening. J. Biomol. Screen. 1, 75-80 (1996).
39. 1-adrenoceptors. Br. J. Pharmacol. 129, 1339-1346 (2000).
40. Nickolls, S. A., Fleck, B., Hoare, S. R. & Maki, R. A. Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states. J. Pharmacol. Exp. Ther. 313, 1281-1288 (2005).
41. Gopalakrishnan, S. M. et al. An offline-addition format for identifying GPCR modulators by screening 384-well mixed compounds in the FLIPR. J. Biomol. Screen. 10, 46-55 (2005).
42. Patel, K. et al. Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. Eur. J. Pharmacol. 430, 203-210 (2001).
43. m dye: On-target and off-target effects of diverse pharma-cological agents. J. Biomol. Screen. 11, 29-39 (2005).
44. Benjamin, E. R. et al. Validation of a fluorescent imaging plate reader membrane potential assay for high-throughput screening of glycine transporter modulators. J. Biomol. Screen. 10, 365-373 (2005).
45. Giuliano, K. A. & Taylor, D. L. Fluorescent-protein biosensors: New tools for drug discovery. Trends Biotechnol. 16, 135-140 (1998).
46. Ghosh, R. N., Grove, L. & Lapets, O. A quantitative cell-based high-content screening assay for the epidermal growth factor receptor-specific activation of mitogen-activated protein kinase. Assay. Drug Dev. Technol. 2, 473-481 (2004).
47. Kapur, R. Fluorescence imaging and engineered biosensors: Functional and activity-based sensing using high content screening. Ann. NY Acad. Sci. 961, 196-197 (2002).
48. Grepin, C. et al. Increasing the quality of compounds isolated during primary screening: High content screening with Acumen Explorer. Curr. Drug Discov. 3, 37-42 (2003).
49. Jager, S. et al. A modular, fully integrated ultra-high-throughput screening system based on confocal fluorescence analysis techniques. J. Biomol. Screen. 8, 648-659 (2003).
50. Oakley, R. H. et al. The cellular distribution of fluorescently labeled arrestins provides a robust, sensitive, and universal assay for screening G protein-coupled receptors. Assay. Drug Dev. Technol. 1, 21-30 (2002).
51. Fowler, A., Davies, I. & Norey, C. A multi-modality assay platform for ultra-high throughput screening. Curr. Pharm. Biotechnol. 1, 265-281 (2000).
52. Almholt, D. L. et al. Nuclear export inhibitors and kinase inhibitors identified using a MAPK-activated protein kinase 2 redistribution screen. Assay. Drug Dev. Technol. 2, 7-20 (2004).
53. Almholt, K. et al. Changes in intracellular cAMP reported by a redistribution assay using a cAMP-dependent protein kinase-green fluorescent protein chimera. Cell Signal. 16, 907-920 (2004).
54. Bertelsen, M. & Sanfridson, A. Inflammatory pathway analysis using a high content screening platform. Assay. Drug Dev. Technol. 3, 261-271 (2005).
55. Li, Z. et al. Identification of gap junction blockers using automated fluorescence microscopy imaging. J. Biomol. Screen. 8, 489-499 (2003).
56. Lundholt, B. K. et al. Identification of Akt pathway inhibitors using redistribution screening on the FLIPR and the IN Cell 3000 analyzer. J. Biomol. Screen. 10, 20-29 (2005).
57. Borchert, K. M. et al. High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay. Drug Dev. Technol. 3, 133-141 (2005).
58. Horrocks, C., Halse, R., Suzuki, R. & Shepherd, P. R. Human cell systems for drug discovery. Curr. Opin. Drug Discov. Devel. 6, 570-575 (2003).
59. Obinata, M. Possible applications of conditionally immortalized tissue cell lines with differentiation functions. Biochem. Biophys. Res. Commun. 286, 667-672 (2001).
60. McNeish, J. Embryonic stem cells in drug discovery. Nature Rev. Drug Discov. 3, 70-80 (2004).
61. Allen, M. et al. Deficiency of the stress kinase p38α results in embryonic lethality: Characterization of the kinase dependence of stress responses of enzymedeficient embryonic stem cells. J. Exp. Med. 191, 859-870 (2000).
62. Levenberg, S., Golub, J. S., Amit, M., Itskovitz-Eldor, J. & Langer, R. Endothelial cells derived from human embryonic stem cells. Proc. Natl Acad. Sci. USA 99, 4391-4396 (2002).
63. Trounson, A. The production and directed differentiation of human embryonic stem cells. Endocr. Rev. 24 Jan 2006 [epub ahead of print].
64. Laschinski, G., Vogel, R. & Spielmann, H. Cytotoxicity test using blastocyst-derived euploid embryonal stem cells: A new approach to in vitro teratogenesis screening. Reprod. Toxicol. 5, 57-64 (1991).
65. Mitchell, K. E. et al. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 21, 50-60 (2003).
66. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
67. Ulrich, R. & Friend, S. H. Toxicogenomics and drug discovery: Will new technologies help us produce better drugs? Nature Rev. Drug Discov. 1, 84-88 (2002).
68. Smith, D. A. & van de, W. H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol. 3, 373-378 (1999).
69. Waters, M. D. & Fostel, J. M. Toxicogenomics and systems toxicology: aims and prospects. Nature Rev. Genet. 5, 936-948 (2004).
70. Riley, R. J. & Kenna, J. G. Cellular models for ADMET predictions and evaluation of drug-drug interactions. Curr. Opin. Drug Discov. Dev. 7, 86-99 (2004).
71. Nersesyan, K., Melikyan, G. S. & Stopper, H. Genotoxic activity of newly synthesized derivatives of cyano-pyridone in murine cells in vivo and in vitro. Tsitol. Genet. 38, 44-48 (2004).
72. Tice, R. R. et al. Report from the working group on the in vivo mammalian bone marrow chromosomal aberration test. Mutat. Res. 312, 305-312 (1994).
73. Fenech, M. In vitro micronucleus technique to predict chemosensitivity. Methods Mol. Med. 111, 3-32 (2005).
74. Fenech, M. The cytokinesis-block micronucleus technique and its application to genotoxicity studies in human populations. Environ. Health Perspect. 101 (Suppl. 3), 101-107 (1993).
75. Ekins, S., Nikolsky, Y. & Nikolskaya, T. Techniques: Application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 26, 202-209 (2005).
76. Pritchard, J. F. et al. Making better drugs: Decision gates in non-clinical drug development. Nature Rev. Drug Discov. 2, 542-553 (2003).
77. Lesko, L. J. & Atkinson, A. J. Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41, 347-366 (2001).
78. Frank, R. & Hargreaves, R. Clinical biomarkers in drug discovery and development. Nature Rev. Drug Discov. 2, 566-580 (2003).
79. De Meyer, G. & Shapiro, F. Biomarker development: The road to clinical utility. Curr. Drug Discov. 12, 23-37 (2003).
80. Rolan, P., Atkinson, A. J. Jr & Lesko, L. J. Use of biomarkers from drug discovery through clinical practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin. Pharmacol. Ther. 73, 284-291 (2003).
81. Koop, R. Combinatorial biomarkers: From early toxicology assays to patient population profiling. Drug Discov. Today 10, 781-788 (2005).
82. Nishimura, T. et al. Disease proteomics toward bedside reality. J. Gastroenterol. 40 (Suppl. 16), 7-13 (2005).
83. Liu, E. T. Expression genomics and drug development: Towards predictive pharmacology. Brief. Funct. Genomic. Proteomic. 3, 303-321 (2005).
84. Shibazaki, M., Takeuchi, T., Ahmed, S. & Kikuchia, H. Blockade by SB203580 of Cyp1a1 induction by 2,3, 7,8-tetrachlorodibenzo-p-dioxin, and the possible mechanism: Possible involvement of the p38 mitogen-activated protein kinase pathway in shuttling of Ah receptor overexpressed in COS-7 cells. Ann. NY Acad. Sci. 1030, 275-281 (2004).
85. Traxler, P. et al. AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64, 4931-4941 (2004).
86. Koga, H. et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol. 45, 1622-1630 (2005).
87. Bick, R. J. et al. Fluorescence imaging microscopy of cellular markers in ischemic vs non-ischemic cardiomyopathy after left ventricular unloading. J. Heart Lung Transplant. 24, 454-461 (2005).
88. Kelloff, G. J. & Sigman, C. C. New science-based endpoints to accelerate oncology drug development. Eur. J. Cancer 41, 491-501 (2005).
89. Swanson, B. N. Delivery of high-quality biomarker assays. Dis. Markers 18, 47-56 (2002).
90. Colburn, W. A. Biomarkers in drug discovery and development: From target identification through drug marketing. J. Clin. Pharmacol. 43, 329-341 (2003).
91. Rathbun, R. C. Surrogate markers for assessing treatment response in HIV disease. Ann. Pharmacother. 27, 450-455 (1993).
92. Perlman, Z. E. et al. Multidimensional drug profiling by automated microscopy. Science 306, 1194-1198 (2004).
93. Nolan, J. P., Lauer, S., Prossnitz, E. R. & Sklar, L. A. Flow cytometry: a versatile tool for all phases of drug discovery. Drug Discov. Today 4, 173-180 (1999).
94. Asadullah, K., Sterry, W. & Volk, H. D. Analysis of cytokine expression in dermatology. Arch. Dermatol. 138, 1189-1196 (2002).
95. Duramad, P., McMahon, C. W., Hubbard, A., Eskenazi, B. & Holland, N. T. Flow cytometric detection of intracellular TH1/TH2 cytokines using whole blood: Validation of immunologic biomarker for use in epidemiologic studies. Cancer Epidemiol. Biomarkers Prev. 13, 1452-1458 (2004).
96. de Weck, A. L. et al. Lymphocyte proliferation, lymphokine production, and lymphocyte receptors in ageing and various clinical conditions. Springer Semin. Immunopathol. 7, 273-289 (1984).
97. Lacombe, F. & Belloc, F. Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Hematol. Cell Ther. 38, 495-504 (1996).
98. Krutzik, P. O., Irish, J. M., Nolan, G. P. & Perez, O. D. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin. Immunol. 110, 206-221 (2004).
99. Medintz, I. L., Uyeda, H. T., Goldman, E. R. & Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. Nature Mater. 4, 435-446 (2005).
100. Rubart, M. Two-photon microscopy of cells and tissue. Circ. Res. 95, 1154-1166 (2004).
101. Paris, S. & Sesboue, R. Metastasis models: The green fluorescent revolution? Carcinogenesis 25, 2285-2292 (2004).
102. Chishima, T. et al. Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res. 57, 2042-2047 (1997).
103. Kan, Z. & Liu, T. J. Video microscopy of tumor metastasis: Using the green fluorescent protein (GFP) gene as a cancer-cell-labeling system. Clin. Exp. Metastasis 17, 49-55 (1999).
104. Rice, B. W., Cable, M. D. & Nelson, M. B. In vivo imaging of light-emitting probes. J. Biomed. Opt. 6, 432-440 (2001).
105. Uhrbom, L., Nerio, E. & Holland, E. C. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nature Med. 10, 1257-1260 (2004).
106. Kumar, S., Kahn, M. A., Dinh, L. & de Vellis, J. NT-3-mediated TrkC receptor activation promotes proliferation and cell survival of rodent progenitor oligodendrocyte cells in vitro and in vivo. J. Neurosci. Res. 54, 754-765 (1998).
107. Gao, X. et al. In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol. 16, 63-72 (2005).
108. Michalet, X. et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-544 (2005).
109. Fischer, H. P. Towards quantitative biology: Integration of biological information to elucidate disease pathways and to guide drug discovery. Biotechnol. Annu. Rev. 11, 1-68 (2005).
110. Butcher, E. C. Can cell systems biology rescue drug discovery? Nature Rev. Drug Discov. 4, 461-467 (2005).
111. Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D. A. & Nolan, G. P. Causal protein-signaling networks derived from multiparameter single-cell data. Science 308, 523-529 (2005).
112. Miyawaki, A., Sawano, A. & Kogure, T. Lighting up cells: Labelling proteins with fluorophores. Nature Cell Biol. (Suppl.), S1-S7 (2003).
113. Zhang, J., Campbell, R. E., Ting, A. Y. & Tsien, R. Y. Creating new fluorescent probes for cell biology. Nature Rev. Mol. Cell Biol. 3, 906-918 (2002).
114. Verkhusha, V. V. & Lukyanov, K. A. The molecular properties and applications of Anthozoa fluorescent proteins and chromoproteins. Nature Biotechnol. 22, 289-296 (2004).
115. Lukyanov, K. A., Chudakov, D. M., Lukyanov, S. & Verkhusha, V. V. Innovation: Photoactivatable fluorescent proteins. Nature Rev. Mol. Cell Biol. 6, 885-891 (2005).
116. Hercend, T. et al. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: A feasibility trial in metastatic renal cell carcinoma. J. Biol. Response Mod. 9, 546-555 (1990).
117. Nagy, R. D. et al. Stem cell transplantation as a therapeutic approach to organ failure. J. Surg. Res. 129, 152-160 (2005).
118. Nir, T. & Dor, Y. How to make pancreatic β cells - prospects for cell therapy in diabetes. Curr. Opin. Biotechnol. 16, 524-529 (2005).
119. Keller, G. Embryonic stem cell differentiation: Emergence of a new era in biology and medicine. Genes Dev. 19, 1129-1155 (2005).
120. Wollert, K. C. et al. Intracoronary autologous bonemarrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 364, 141-148 (2004).
121. Tang, Y. L. Cellular therapy with autologous skeletal myoblasts for ischemic heart disease and heart failure. Methods Mol. Med. 112, 193-204 (2005).
122. Sykes, M. & Nikolic, B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature 435, 620-627 (2005).
123. Radbruch, A. & Thiel, A. Cell therapy for autoimmune diseases: Does it have a future? Ann. Rheum. Dis. 63 (Suppl. 2), ii96-ii101 (2004).
124. Mattson, M. P. Emerging neuroprotective strategies for Alzheimer's disease: Dietary restriction, telomerase activation, and stem cell therapy. Exp. Gerontol. 35, 489-502 (2000).
125. Tuszynski, M. H. et al. A Phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Med. 11, 551-555 (2005).
126. Brundin, P. et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123, 1380-1390 (2000).
127. Widner, H. et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 327, 1556-1563 (1992).
128. Bulte, J. W. Hot spot MRI emerges from the background. Nature Biotechnol. 23, 945-946 (2005).
129. Eriksson, P. S. et al. Neurogenesis in the adult human hippocampus. Nature Med. 4, 1313-1317 (1998).
130. Zhu, J., Wu, X. & Zhang, H. L. Adult neural stem cell therapy: Expansion in vitro, tracking in vivo and clinical transplantation. Curr. Drug Targets 6, 97-110 (2005).
131. Frangioni, J. V. & Hajjar, R. J. In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation 110, 3378-3383 (2004).
132. Vogt, A. et al. Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem. Biol. 10, 733-742 (2003).
133. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).